DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus
UMass Chan Affiliations
Department of PediatricsDepartment of Pathology
Department of Medicine, Division of Infectious Diseases and Immunology
Document Type
Journal ArticlePublication Date
2013-10-01Keywords
AnimalsAntibodies, Viral
Cytomegalovirus
Cytomegalovirus Vaccines
Female
Interferon-gamma
Mice
Mice, Inbred BALB C
T-Lymphocytes
Vaccines, Attenuated
Vaccines, DNA
Immunology of Infectious Disease
Immunopathology
Immunoprophylaxis and Therapy
Metadata
Show full item recordAbstract
As a leading cause of congenital infection and a major threat to immunocompromised individuals, human cytomegalovirus (HCMV) is a major global public health concern. Effective HCMV vaccines would need to induce potent and balanced humoral and cellular immune responses. In this pilot study, immunogenicity studies were conducted in mice to examine HCMV antigen-specific antibody and T cell responses when a heterologous prime-boost immunization strategy was tested. DNA vaccines expressing either targets of protective antibody responses (gB and gM/gN) or well characterized T cell immunogens (pp65, pp150, and IE1) were used as the priming immunization while the live attenuated HCMV vaccine Towne strain was used as the boost, which may act like an inactivated vaccine due to the inability of HCMV to replicate in a mouse host. Our data indicate that while DNA vaccines were effective in priming HCMV-specific antibody responses, the final titers of gB- or gM-specific antibodies were not much different from those elicited by using multiple immunizations of HCMV alone. In contrast, DNA priming significantly enhanced T cell responses against gB, pp65, and IE1 as measured by IFN-gamma. However, HCMV alone was not effective in eliciting strong T cell immune responses when used in a mouse host. Our data indicate that the complexity of antigen composition from a large virus, such as HCMV, may affect the profile of immune responses when viral vaccines are used as a boost.Source
Hum Vaccin Immunother. 2013 Oct;9(10):2120-32. doi: 10.4161/hv.25750. Epub 2013 Jul 25. Link to article on publisher's siteDOI
10.4161/hv.25750Permanent Link to this Item
http://hdl.handle.net/20.500.14038/30482PubMed ID
24051429Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.4161/hv.25750